Ovid Therapeutics Inc. financial data

Symbol
OVID on Nasdaq
Location
New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 486 % -35.9%
Debt-to-equity 38.2 % -23.4%
Return On Equity -63.7 % -62.4%
Return On Assets -46.1 % -76.1%
Operating Margin -618 % +94.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.2M shares +0.29%
Common Stock, Shares, Outstanding 71.2M shares +0.2%
Entity Public Float 45.9M USD -76%
Common Stock, Value, Issued 71K USD 0%
Weighted Average Number of Shares Outstanding, Basic 71M shares +0.51%
Weighted Average Number of Shares Outstanding, Diluted 71M shares +0.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.61M USD +946%
Research and Development Expense 24.9M USD -39.9%
General and Administrative Expense 22.6M USD -20.9%
Operating Income (Loss) -40.9M USD +41.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -36.3M USD -11.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -36.3M USD -11.8%
Earnings Per Share, Basic 0 USD/shares +33.3%
Earnings Per Share, Diluted 0 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6M USD +37.3%
Cash, Cash Equivalents, and Short-term Investments 25.6M USD -59.2%
Assets, Current 28.8M USD -56.2%
Property, Plant and Equipment, Net 269K USD -47.2%
Operating Lease, Right-of-Use Asset 11.9M USD -8.9%
Other Assets, Noncurrent 0 USD -100%
Assets 63.8M USD -37.8%
Accounts Payable, Current 1.71M USD -36.9%
Employee-related Liabilities, Current 1.85M USD -57.1%
Accrued Liabilities, Current 2.96M USD -61.1%
Liabilities, Current 6.8M USD -41.6%
Operating Lease, Liability, Noncurrent 12.4M USD -10.2%
Liabilities 19.2M USD -27.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -126K USD -450%
Retained Earnings (Accumulated Deficit) -331M USD -12.3%
Stockholders' Equity Attributable to Parent 44.7M USD -41.4%
Liabilities and Equity 63.8M USD -37.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.3M USD +38.4%
Net Cash Provided by (Used in) Financing Activities 13K USD -94.3%
Net Cash Provided by (Used in) Investing Activities 5.1M USD -74.7%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 71.2M shares +0.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 22.5M USD +33%
Deferred Tax Assets, Valuation Allowance 89.5M USD -3.41%
Deferred Tax Assets, Gross 92.6M USD +25.7%
Depreciation 256K USD -34.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -36.5M USD -12.2%
Lessee, Operating Lease, Liability, to be Paid 17.6M USD -11.7%
Operating Lease, Liability, Current 1.41M USD +7.31%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.32M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.32M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.47M USD +6.61%
Deferred Tax Assets, Operating Loss Carryforwards 62.1M USD +11.6%
Preferred Stock, Shares Issued 1.25K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.47M USD 0%
Additional Paid in Capital 376M USD +1.32%
Preferred Stock, Shares Outstanding 1.25K shares 0%
Amortization of Intangible Assets 147K USD +8.89%
Depreciation, Depletion and Amortization 141K USD +3.68%
Share-based Payment Arrangement, Expense 4.87M USD -28.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%